Showing results (311-320 of 376) with videos related to
Sort By:
Pageof 38
Current HIV Research|October 16, 2012
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive studyDaniel Podzamczer, Esteban Martínez, Pere Domingo, et al.HIV Medicine|March 29, 2023
Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohortJorge Palacio-Vieira, Sergio Moreno-Fornés, Yesika Díaz, et al.International Journal of Molecular Sciences|February 26, 2022
Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4<sup>+</sup> T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral TherapyElena Yeregui, Jenifer Masip, Consuelo Viladés, et al.The Journal of Antimicrobial Chemotherapy|November 8, 2008
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohortManuel Crespo, Esteban Ribera, Ignacio Suárez-Lozano, et al.The Lancet. Infectious Diseases|June 12, 2015
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trialJosé R Arribas, Pierre-Marie Girard, Roland Landman, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, Esteban Ribera, María Lagarde, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 StudyHernando Knobel, José M Miró, Beatriz Mahillo, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 20, 2020
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European StudySarah Amele, Lars Peters, Alison Rodger, et al.The Journal of Antimicrobial Chemotherapy|March 22, 2008
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohortPere Domingo, Ignacio Suárez-Lozano, Ferran Torres, et al.Microorganisms|November 25, 2023
Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide StudyRaquel Martín-Iguacel, Carles Pericas, Andreu Bruguera, et al.Pageof 38